Influence of Hyaluronan Density on the Behavior of Breast Cancer Cells with Different CD44 Expression (Adv. Healthcare Mater. 4/2022)

Carvalho, Ana M.; Costa, Diana Soares da; Reis, Rui L.; Pashkuleva, Iva

doi:10.1002/adhm.202270021

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both collagen I and HA are important ECM components of breast cancer TME. Previous studies in the literature have demonstrated that HA interacts with breast cancer cells via CD44 receptors [ 34 ] and the addition of HA can better mimic the biophysical and biochemical microenvironments in breast cancer ECM. [ 35,36 ] Therefore, we attempted to prepare a bioink composing both HA and collagen.…”

Section: Resultsmentioning

confidence: 99%

Embedded Bioprinting of Breast Tumor Cells and Organoids Using Low‐Concentration Collagen‐Based Bioinks

Shi,

Mirza,

Kuss

et al. 2023

Adv Healthcare Materials

View full text Add to dashboard Cite

Bioinks for 3D bioprinting of tumor models should not only meet printability requirements but also accurately maintain and support phenotypes of tumor surrounding cells to recapitulate key tumor hallmarks. Collagen is a major extracellular matrix protein for solid tumors, but low viscosity of collagen solution has made 3D bioprinted cancer models challenging. This work produces embedded, bioprinted breast cancer cells and tumor organoid models using low‐concentration collagen I based bioinks. The biocompatible and physically crosslinked silk fibroin hydrogel is used to generate the support bath for the embedded 3D printing. The composition of the collagen I based bioink is optimized with a thermoresponsive hyaluronic acid‐based polymer to maintain the phenotypes of both the noninvasive epithelial and invasive breast cancer cells, as well as cancer‐associated fibroblasts. Mouse breast tumor organoids are bioprinted using optimized collagen bioink to mimic in vivo tumor morphology. A vascularized tumor model is also created using a similar strategy, with significantly enhanced vasculature formation under hypoxia. This study shows the great potential of embedded bioprinted breast tumor models utilizing a low‐concentration collagen‐based bioink for advancing the understanding of tumor cell biology and facilitating drug discovery research.

show abstract

Section: Resultsmentioning

confidence: 99%

Embedded Bioprinting of Breast Tumor Cells and Organoids Using Low‐Concentration Collagen‐Based Bioinks

Shi,

Mirza,

Kuss

et al. 2023

Adv Healthcare Materials

View full text Add to dashboard Cite

show abstract

“…CD44, a glycoprotein on the surface of the cell, participates in immune recognition, cell‐to‐cell and cell‐to‐matrix interactions, cell migration, and other processes. [ 74 ] HA is a promising ligand for targeting CD44‐overexpressing breast cancer cells, such as MDA‐MB‐231 cells (Figure 5b ). However, HA‐modified drug carriers accumulate preferentially in the liver after systemic injection, thereby resulting in insufficient accumulation in tumor tissues.…”

Section: Fluorescent Prodrug Systems For Breast Cancermentioning

confidence: 99%

Cancer Cell‐Specific Fluorescent Prodrug Delivery Platforms

Kim

Chen

et al. 2023

Advanced Science

View full text Add to dashboard Cite

Targeting cancer cells with high specificity is one of the most essential yet challenging goals of tumor therapy. Because different surface receptors, transporters, and integrins are overexpressed specifically on tumor cells, using these tumor cell-specific properties to improve drug targeting efficacy holds particular promise. Targeted fluorescent prodrugs not only improve intracellular accumulation and bioavailability but also report their own localization and activation through real-time changes in fluorescence. In this review, efforts are highlighted to develop innovative targeted fluorescent prodrugs that efficiently accumulate in tumor cells in different organs, including lung cancer, liver cancer, cervical cancer, breast cancer, glioma, and colorectal cancer. The latest progress and advances in chemical design and synthetic considerations in fluorescence prodrug conjugates and how their therapeutic efficacy and fluorescence can be activated by tumor-specific stimuli are reviewed. Additionally, novel perspectives are provided on strategies behind engineered nanoparticle platforms self-assembled from targeted fluorescence prodrugs, and how fluorescence readouts can be used to monitor the position and action of the nanoparticle-mediated delivery of therapeutic agents in preclinical models. Finally, future opportunities for fluorescent prodrug-based strategies and solutions to the challenges of accelerating clinical translation for the treatment of organ-specific tumors are proposed.

show abstract

Influence of Hyaluronan Density on the Behavior of Breast Cancer Cells with Different CD44 Expression (Adv. Healthcare Mater. 4/2022)

Cited by 2 publications

References 0 publications

Embedded Bioprinting of Breast Tumor Cells and Organoids Using Low‐Concentration Collagen‐Based Bioinks

Embedded Bioprinting of Breast Tumor Cells and Organoids Using Low‐Concentration Collagen‐Based Bioinks

Cancer Cell‐Specific Fluorescent Prodrug Delivery Platforms

Contact Info

Product

Resources

About